Skip to main content

Table 1 Summary of targets, toxicity, and evaluation at ASCO 2008 of novel agents in advanced breast cancer.

From: Novel therapies in breast cancer: what is new from ASCO 2008

Agent

Target

Toxicity

Evaluation at ASCO

Lapatinib

EGFR/HER2

Diarrhea, rash, nausea, vomiting

-monotherapy in inflammatory BC

   

-c/w trastuzumab

   

-c/w bevacizumab

HKI-272

Pan HER

Diarrhea, nausea

n/a

Trastuzumab DM-1

HER2

Transaminitis, fatigue, thrombocytopenia, anemia, neuropathy

-monotherapy refractory to trastuzumab

Pertuzumab

HER2

Diarrhea, pain, nausea, vomiting, mucositis

-c/w trastuzumab

Tanespimycin

HSP 90

Fatigue, diarrhea, dizziness, headache

-c/w trastuzumab

Cetuximab

EGFR

Rash, diarrhea, nausea, vomiting

-c/w carboplatin in triple negative BC

   

-c/w irinotecan

Bevacizumab

VEGF

Hypertension, proteinuria, bleeding, thromboembolism

-c/w lapatinib

   

-c/w docetaxel

   

-c/w nab-paclitaxel

Gefitinib

EFGR

Rash, diarrhea, nausea, vomiting

-c/w anastrazole

RAD001

mTOR

Stomatitis, fatigue, anorexia, diarrhea, headache, rash

-c/w anastrazole

   

-c/w paclitaxel and trastuzumab

   

-c/w navelbine and trastuzumab

Pazopanib

VEGFR, PDGFR, C-kit

Diarrhea, rash, nausea

-c/w lapatinib

Sunitinib

VEGFR, PDGFR, C-kit

Mucositis, fatigue, nausea, diarrhea

n/a

Axitinib

VEGFR 1,2, PDGFR, C-kit

Diarrhea, nausea, alopecia, stomatitis

n/a

C1311

Topoisomerase II

Neutropenia

-monotherapy in refractory BC

Pemetrexed

Anti-folate

Myelosuppression, anemia

-1st line monotherapy in advanced BC

Larotaxel

Cytotoxic

Neutropenia, fatigue

-c/w trastuzumab

Orataxel

Cytotoxic

Neutropenia, fatigue, peripheral neuropathy

-monotherapy in taxane resistant BC

  1. Abbreviations: ASCO; American Society of Clinical Oncology; EGFR, epidermal growth factor receptor; HER, human epidermal receptor; BC, breast cancer; c/w, combination with; n/a, not applicable; HSP, heat shock protein; VEGF, vascular endothelial growth factor; mTOR, mammalian target of rapamycin; VEGFR, vascular endothelial growth factor receptor; PDGFR, platelet derived growth factor receptor